Skip to main content
Premium Trial:

Request an Annual Quote

Morewood Licenses High-Throughput Technology from Harvard

NEW YORK, Feb. 11 - Morewood Molecular Sciences has licensed high-throughput technology from Harvard University that the company hopes will "leverage" its own technology for ultra-fast enzymatics.

The license, which covers a method of high-throughput screening of certain undisclosed molecules, may "enhances Morewood's foundation technology for some applications, for ultra high throughput assaying of enzyme activity, and for point-of-care diagnostics," the company said on Monday. In return, Harvard agreed to acquire an equity interest in the firm.

 

Financial details of the non-exclusive agreement were not disclosed.
 
Morewood, a spin-off of Pittsburgh-based LaunchCyte, is a private company that develops technologies for assaying enzyme activities, including in-vitro diagnostics. It also provides ultra high-throughput screening of drug candidates. Morewood has offices in Pittsburgh and Philadelphia.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.